The prognostic impact of lymphocyte-to-C-reactive protein score in patients undergoing surgical resection for intrahepatic cholangiocarcinoma: A comparative study of major representative inflammatory / immunonutritional markers.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
11
2020
accepted:
08
01
2021
entrez:
28
1
2021
pubmed:
29
1
2021
medline:
24
6
2021
Statut:
epublish
Résumé
In many malignancies including intrahepatic cholangiocarcinoma (iCCA), prognostic significance of host-related inflammatory / immunonutritional markers have attracted a lot of attention. However, it is unclear which is the strongest prognostic indicator for iCCA among these markers. The aim of this study was to firstly evaluate the prognostic utility of inflammatory / immunonutritional markers in resected iCCA patients using a multiple comparison in addition to a new marker, lymphocyte-to-C-reactive protein (CRP) score. A total of sixty iCCA patients, who underwent surgical resection between October 2004 and April 2019, were enrolled in this study. Their clinical and pathological data were retrospectively assessed using univariate and multivariate analysis to determine prognostic predictors for disease specific survival (DSS). Moreover, these patients, who were divided into high and low groups based on lymphocyte-to-CRP score, were compared these survival outcomes using Kaplan-Meier analysis with a log-rank test. In multivariate analysis, the significant prognostic factors were preoperative lymphocyte-to-CRP score (p = 0.008), preoperative CRP-to-albumin ratio (CAR; p = 0.017), pathological T category (p = 0.003), and pathological vascular invasion (p < 0.001). Resected iCCA patients with a low lymphocyte-to-CRP score (score 0) had significant better prognosis than patients with a high score (score 1 or 2) (p = 0.016). Notably, the mortality of the high lymphocyte-to-CRP score group did not show statistically difference from the poor mortality of unresected iCCA patients (p = 0.204). Preoperative lymphocyte-to-CRP score was the strongest prognostic indicator in iCCA patients with surgical resection. In these patients, early intervention with nutritional support should be considered prior to operation.
Sections du résumé
BACKGROUND
In many malignancies including intrahepatic cholangiocarcinoma (iCCA), prognostic significance of host-related inflammatory / immunonutritional markers have attracted a lot of attention. However, it is unclear which is the strongest prognostic indicator for iCCA among these markers. The aim of this study was to firstly evaluate the prognostic utility of inflammatory / immunonutritional markers in resected iCCA patients using a multiple comparison in addition to a new marker, lymphocyte-to-C-reactive protein (CRP) score.
METHODS
A total of sixty iCCA patients, who underwent surgical resection between October 2004 and April 2019, were enrolled in this study. Their clinical and pathological data were retrospectively assessed using univariate and multivariate analysis to determine prognostic predictors for disease specific survival (DSS). Moreover, these patients, who were divided into high and low groups based on lymphocyte-to-CRP score, were compared these survival outcomes using Kaplan-Meier analysis with a log-rank test.
RESULTS
In multivariate analysis, the significant prognostic factors were preoperative lymphocyte-to-CRP score (p = 0.008), preoperative CRP-to-albumin ratio (CAR; p = 0.017), pathological T category (p = 0.003), and pathological vascular invasion (p < 0.001). Resected iCCA patients with a low lymphocyte-to-CRP score (score 0) had significant better prognosis than patients with a high score (score 1 or 2) (p = 0.016). Notably, the mortality of the high lymphocyte-to-CRP score group did not show statistically difference from the poor mortality of unresected iCCA patients (p = 0.204).
CONCLUSIONS
Preoperative lymphocyte-to-CRP score was the strongest prognostic indicator in iCCA patients with surgical resection. In these patients, early intervention with nutritional support should be considered prior to operation.
Identifiants
pubmed: 33507925
doi: 10.1371/journal.pone.0245946
pii: PONE-D-20-35722
pmc: PMC7842956
doi:
Substances chimiques
Biomarkers
0
C-Reactive Protein
9007-41-4
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0245946Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Cancer Treat Rev. 2015 Dec;41(10):971-8
pubmed: 26481060
Br J Surg. 2014 Jan;101(2):79-88
pubmed: 24375300
Abdom Radiol (NY). 2020 Nov;45(11):3662-3680
pubmed: 32417933
Liver Int. 2020 Mar;40(3):704-711
pubmed: 31773848
Nutr Cancer. 1999;35(2):106-10
pubmed: 10693162
Anticancer Res. 2013 Dec;33(12):5591-5
pubmed: 24324103
Bratisl Lek Listy. 2001;102(1):5-14
pubmed: 11723675
Onco Targets Ther. 2016 Oct 19;9:6417-6423
pubmed: 27799789
BMC Cancer. 2016 Oct 12;16(1):792
pubmed: 27733196
Oncol Lett. 2019 Jan;17(1):165-174
pubmed: 30655752
Clin Sci (Lond). 1999 Aug;97(2):215-23
pubmed: 10409477
HPB (Oxford). 2007;9(6):456-60
pubmed: 18345294
Am J Surg Pathol. 2017 Dec;41(12):1630-1641
pubmed: 28945626
Ann Surg Oncol. 2007 Oct;14(10):2798-806
pubmed: 17632760
Oncotarget. 2016 Aug 9;7(32):50963-50971
pubmed: 26918355
Nat Commun. 2014 Dec 15;5:5696
pubmed: 25526346
Biosci Trends. 2020 Sep 21;14(4):304-309
pubmed: 32507777
J Hepatol. 2014 Jun;60(6):1268-89
pubmed: 24681130
Int J Surg. 2016 Jul;31:93-9
pubmed: 27267949
Am J Surg. 2012 Oct;204(4):416-21
pubmed: 23010614
Br J Cancer. 2003 Sep 15;89(6):1028-30
pubmed: 12966420
Ann Surg. 2020 Aug;272(2):342-351
pubmed: 32675548
Medicine (Baltimore). 2015 Nov;94(46):e2006
pubmed: 26579806
World J Surg. 2010 Feb;34(2):285-90
pubmed: 19997918
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588
pubmed: 32606456
Am J Surg. 1998 Oct;176(4):335-8
pubmed: 9817250
Tumour Biol. 2015 Jul;36(7):5283-9
pubmed: 25672606
Cancers (Basel). 2019 Apr 10;11(4):
pubmed: 30974894
J Hepatol. 2004 Mar;40(3):472-7
pubmed: 15123362
Cancer Med. 2019 Oct;8(13):5916-5929
pubmed: 31429524
J Surg Oncol. 2008 May 1;97(6):513-8
pubmed: 18335453
Hepatol Res. 2014 Oct;44(10):E118-28
pubmed: 24397273
PLoS One. 2014 Jun 26;9(6):e101119
pubmed: 24968121
Nutr Cancer. 2001;39(2):210-3
pubmed: 11759282
Oncotarget. 2018 Jan 11;9(17):13934-13947
pubmed: 29568406
J Epidemiol Community Health. 2007 Sep;61(9):824-33
pubmed: 17699539
Surg Today. 2020 Apr;50(4):379-388
pubmed: 31667580
Mol Clin Oncol. 2017 Apr;6(4):566-574
pubmed: 28413670
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
Clin Nutr. 2020 Apr;39(4):1209-1217
pubmed: 31155370
JAMA Surg. 2014 Jun;149(6):565-74
pubmed: 24718873
Nutr Hosp. 2005 Jan-Feb;20(1):38-45
pubmed: 15762418
World J Surg. 2018 Apr;42(4):1085-1091
pubmed: 28887635
BMC Cancer. 2011 Feb 10;11:64
pubmed: 21306650
Medicine (Baltimore). 2015 Apr;94(13):e574
pubmed: 25837750
J Surg Oncol. 2008 Dec 1;98(7):540-4
pubmed: 18937231
Cancer Manag Res. 2019 Oct 30;11:9107-9119
pubmed: 31802940
Cancer Treat Rev. 2013 Aug;39(5):534-40
pubmed: 22995477
Br J Cancer. 2006 Jan 30;94(2):275-80
pubmed: 16421594
Semin Cancer Biol. 2004 Dec;14(6):433-9
pubmed: 15489136
Lancet Oncol. 2014 Oct;15(11):e493-503
pubmed: 25281468
J Clin Lab Anal. 2019 Nov;33(9):e22999
pubmed: 31418936
J Surg Oncol. 2018 Sep;118(3):422-430
pubmed: 30084163
Med Oncol. 2013 Mar;30(1):352
pubmed: 23275140